RenuTend RSS Authorised This medicine is authorised for use in the European Union tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cellsMedicineVeterinaryAuthorised
Page contentsPage contents Overview Product details Authorisation details Assessment history News on RenuTend More information on RenuTend Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website Product details Name of medicine RenuTend Active substance tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells International non-proprietary name (INN) or common name tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells Pharmacotherapeutic groupMusculo-skeletal systemOther drugs for disorders of the musculo-skeletal system Authorisation details EMA product number EMEA/V/C/005428 Assessment history Initial marketing authorisation documents CVMP summary of positive opinion for RenuTendAdopted Reference Number: EMA/CVMP/73401/2022 English (EN) (131.59 KB - PDF)First published: 21/02/2022 View News on RenuTend Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 9-10 September 202512/09/2025 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 November 202408/11/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 December 202308/12/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 11-13 July 202314/07/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-16 February 202221/02/2022 More information on RenuTend Arti-Cell Forte / RenuTend - direct animal healthcare professional communication (DaHPC) This page was last updated on 21/02/2022 Share this page